RDY Dr. Reddy's Laboratories Ltd. ADS

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Dr. Reddy’s Laboratories Ltd. – RDY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) resulting from allegations that Dr. Reddy’s may have issued materially misleading business information to the investing public.

On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. On this news, shares of Dr. Reddy’s fell $11.75 per share or 18.01% to close at $53.50 on November 6, 2015. Then, on August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany (Regierung von Oberbayern), following a recent inspection of the plant, did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in Hyderabad, India. On this news, shares of Dr. Reddy’s fell sharply during intraday trading on August 10, 2017, damaging investors.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Dr. Reddy’s investors. If you purchased shares of Dr. Reddy’s, please visit the firm’s website at http://www.rosenlegal.com/cases-1191.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
10/08/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dr. Reddy's Laboratories Ltd. ADS

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bulls Still In Driver's Seat, But For How Long? Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. · Sector Relative Strength Rankings & Weighting Recommen...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch